Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 31Squamous Cell Carcinoma of Head and Neck 21Carcinoma, Non-Small-Cell Lung 20Neoplasms 18Breast Neoplasms 18Glioblastoma 17Esophageal Squamous Cell Carcinoma 16Rectal Neoplasms 15Lung Neoplasms 15Esophageal Neoplasms 15Head and Neck Neoplasms 12Uterine Cervical Neoplasms 11Neoplasm Metastasis 10Glioma 10Nasopharyngeal Carcinoma 8Stomach Neoplasms 7Radiation Injuries 7Oropharyngeal Neoplasms 7Brain Neoplasms 7Hyperthermia 6Carcinoma, Hepatocellular 6Astrocytoma 6Urinary Bladder Neoplasms 5Small Cell Lung Carcinoma 5Sarcoma 5Oligodendroglioma 5Colorectal Neoplasms 5Carcinoma, Renal Cell 5Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4

Interventions

enfortumab vedotin 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Bladder Cancer × Radiotherapy × Clear all
NCT06434350 2026-03-02

Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
41 enrolled
Genitourinary

Advanced Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡